SCHEMBL3402107

SCHEMBL3402107

Cc1nc(-c2cc(Cl)ccc2Cl)sc1C(=O)NCCCCN1CCCC1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 6/20 0.47
MAPK1 P28482 2/20 0.46
CHRM4 P08173 1/20 0.46
MAPT P10636 3/20 0.45
RAD52 P43351 2/20 0.45
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
TP53 P04637 1/20 0.45
POLB P06746 1/20 0.45
HPGD P15428 1/20 0.45
STAT1 P42224 1/20 0.45
GFER P55789 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
HSD17B10 Q99714 1/20 0.45
KMT2A Q03164 1/20 0.45
GAA P10253 1/20 0.45
SMYD2 Q9NRG4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3404779 0.97 MAPK1 (0.49) DRD2MAPK1CHRM4MAPTRAD52
SCHEMBL3398247 0.93 ALDH1A1 (0.48) DRD2CHRM4ALDH1A1NPSR1GAA
SCHEMBL3403541 0.93 DPP4 (0.48) DRD2MAPK1CHRM4MAPTRAD52
SCHEMBL3405826 0.92 DPP4 (0.49) DRD2CHRM4ALDH1A1NPSR1HSD17B10
SCHEMBL3399569 0.90 MAPK1 (0.49) DRD2MAPK1CHRM4MAPTRAD52
SCHEMBL3404517 0.89 F10 (0.47) DRD2GAASMYD2
SCHEMBL3400482 0.89 DRD2 (0.46) DRD2MAPK1CHRM4MAPTRAD52
SCHEMBL3403787 0.89 SMYD2 (0.50) DRD2CHRM4MAPTALDH1A1LMNA
SCHEMBL3405412 0.88 CHRM4 (0.49) DRD2CHRM4MAPTALDH1A1KMT2A
SCHEMBL3398627 0.86 CHRM4 (0.60) DRD2MAPK1CHRM4MAPTRAD52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues LIGAND PHARMACEUTICALS, INC. (US) 2010-11-25 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
WO-2006089076-A9 THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES NEUROGEN CORP (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues HRH3, HRH4, HRH2 DRD2 1283/4885MAPK1 2771/4885CHRM4 289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.